Role of SOCS3 Evaluated by Immunohistochemical Analysis in a Cohort of Patients Affected by Prostate Cancer: Preliminary Results

Calarco, Alessandro; Pinto, Francesco; Pierconti, Francesco; Sacco, Emilio; Marrucci, Eleonora; Totaro, Angelo; Palermo, Giuseppe; Vittori, Matteo; Bassi, Pierfrancesco

doi:10.5301/ru.2012.9392

Cited by 11 publications

(9 citation statements)

References 19 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the IHC studies, the avidin‐biotin‐peroxidase complex method was performed on paraffin sections applying technical procedures previous reported and using a commercially available kit (Dako LSAB2, Dakopatts, Glostrup, Denmark) and the following commercially available monoclonal antibodies: CK20 (1:200, DAKO, Carpinteria, CA), CD44 (1:640 Pharmingen San Diego CA, p53 (1:200, BioGenex, San Ramon, CA and Ki‐67 (MIB‐1; 1:200, DAKO, Carpinteria, CA), p53 (1:200, BioGenex, San Ramon, CA), and CK20 (1:200, DAKO, Carpinteria, CA).…”

Section: Methodsmentioning

confidence: 99%

Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma

Pierconti

Martini

Straccia

et al. 2018

APMIS

Self Cite

View full text Add to dashboard Cite

In this study, we have examined 67 cytology specimens from patients from 2014 to 2016. The ratio man to women was 4:1 with a median age of 75 years (range: 55-87 years). Thin-Prep processed urinary cytology specimens demonstrated large urothelial cells, with cytologic features of malignancy, thus including hypochromatic nuclei with occasional peripherally accentuated chromatin rim. The cytological diagnosis of High Grade Urothelial Carcinoma (HGUC) was made in 55 patients while 12 specimens were classified as Atypical Urothelial Cells (AUC). This cases represent the 15% of the HGUC and the 4% of the AUC cases diagnosed in our department between 2016 to 2018. Of note, is the fact that in AUC cases, hypochromatic irregular urothelial cells were the only type of cells with malignant features observed in the specimen, and therefore, according to the Paris System criteria, the absence of nuclear hyperchromasia precludes a diagnosis of suspicious high grade urothelial carcinoma (SHGUC) or High Grade Urothelial Carcinoma (HGUC). Subsequent biopsy diagnosis of high grade urothelial carcinoma confirmed the cytological diagnosis of HGUC in 55 patients but also in all 12 patients with a AUC cytologic diagnosis. Our study series support the hypothesis that malignant urothelial cells with hypochromatic nuclei seen in urine cytologic specimens can be diagnostic for HGUC based on their very large nuclei, high nuclear cytoplasmatic ratio (N/C) >0.7, irregular nuclear outlines and coarse (frequently peripheral) chromatin in the absence of hyperchromasia.

show abstract

Section: Methodsmentioning

confidence: 99%

Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma

Pierconti

Martini

Straccia

et al. 2018

APMIS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Elevated levels of the IL-6 cytokine have been found repeatedly in both serum and local tissue samples taken from prostate cancer patients,(52, 53) and suppression of SOCS3 via expression of IL-6 has been implicated in the development(54) and aggressiveness(55) of prostate cancer. These findings may point to an important causal factor for prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Study of DNA Methylation of Inflammatory Genes and Cancer Risk

Joyce

Gao

Liu

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Chronic inflammation plays a key role in cancer etiology. DNA methylation modification, one of the epigenetic mechanisms regulating gene expression, is considered a hallmark of cancer. Human and animal models have identified numerous links between DNA methylation and inflammatory biomarkers. Our objective was to prospectively and longitudinally examine associations between methylation of four inflammatory genes and cancer risk. Methods We included 795 Normative Aging Study participants with blood drawn 1-4 times from 1999-2012 (median follow up 10.6 years). Promoter DNA methylation of IL-6, ICAM-1, IFN, and TLR2 in blood leukocytes was measured using pyrosequencing at multiple CpG sites and averaged by gene for data analysis. We used Cox regression models to examine prospective associations of baseline and time-dependent methylation with cancer risk, and compared mean methylation differences over time between cancer cases and cancer-free participants. Results Baseline IFN hypermethylation was associated with all-cancer (HR=1.49, p=0.04) and prostate cancer incidence (HR=1.69, p=0.02). Baseline ICAM-1 and IL-6 hypermethylation were associated with prostate cancer incidence (HR=1.43, p=0.02; HR=0.70, p=0.03 respectively). In our time-dependent analyses, IFN hypermethylation was associated with all-cancer (HR=1.79, p=0.007) and prostate cancer (HR=1.57, p=0.03) incidence; and ICAM-1 and IL-6 hypermethylation were associated with prostate cancer incidence (HR=1.39, p=0.02; HR=0.69, p=0.03 respectively). We detected significant ICAM-1 hypermethylation in cancer cases (p=0.0003) 10-13 years pre-diagnosis. Conclusion Hypermethylation of IFN and ICAM-1 may play important roles in early carcinogenesis, particularly that of prostate cancer. Impact These methylation changes could inform the development of early detection biomarkers and potential treatments of inflammation-related carcinogenesis.

show abstract

“…As mentioned above, SOCS‐3 is expressed in PCa tissue samples and SOCS‐3 expression increases during the progression of carcinoma. However, other reports have indicated that negative SOCS‐3 staining is correlated with an aggressive tumor behavior . Therefore, SOCS‐3 may have a role as a tumor diagnostic and prognostic marker; further studies are needed to verify this hypothesis using larger sample sizes.…”

Section: Potential Clinical Applications Of Socs‐3 In Pcamentioning

confidence: 91%

“…They concluded that patients lacking SOCS‐3 had a more aggressive disease than patients expressing SOCS‐3 in cancer tissues. Moreover, patients with partial expression of SOCS‐3 also exhibited a more aggressive disease …”

Section: The Multiple Function Of Socs‐3 In Pcamentioning

confidence: 99%

Characterization of the roles of suppressor of cytokine signaling‐3 in prostate cancer development and progression

Ren

Chen

et al. 2015

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

As negative feedback regulators of cytokine signaling, suppressor of cytokine signaling proteins are induced by interleukins and various peptide hormones and may prevent sustained activation of signaling pathways. In particular, suppressor of cytokine signaling-3 (SOCS-3) plays pivotal roles in the development and progression of various cancers and exerts pleiotropic effects on cell proliferation and apoptosis. In recent years, abnormal expression of SOCS-3 and its multiple functions have been extensively investigated in human carcinomas, particularly in prostate cancer. SOCS-3 can act as an oncogene or a tumor suppressor depending on the cellular context. In this review, we focus on the role of SOCS-3 in prostate cancer development and prognosis, as well as the potential of SOCS-3 as a therapeutic target and diagnostic marker.

show abstract

Role of SOCS3 Evaluated by Immunohistochemical Analysis in a Cohort of Patients Affected by Prostate Cancer: Preliminary Results

Cited by 11 publications

References 19 publications

Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma

Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma

Longitudinal Study of DNA Methylation of Inflammatory Genes and Cancer Risk

Characterization of the roles of suppressor of cytokine signaling‐3 in prostate cancer development and progression

Contact Info

Product

Resources

About